Vempati, R.; Toquica Gahona, C.; Haddad, F.; Manickavelan, H.V.; Zakaria, F.; Hanna, J.; Sanusi, M.; Bhatt, P.; Haddad, R.; Mohammed, F.;
et al. Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence. J. Mol. Pathol. 2026, 7, 25.
https://doi.org/10.3390/jmp7030025
AMA Style
Vempati R, Toquica Gahona C, Haddad F, Manickavelan HV, Zakaria F, Hanna J, Sanusi M, Bhatt P, Haddad R, Mohammed F,
et al. Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence. Journal of Molecular Pathology. 2026; 7(3):25.
https://doi.org/10.3390/jmp7030025
Chicago/Turabian Style
Vempati, Roopeessh, Christian Toquica Gahona, Fadi Haddad, Hari Vorappan Manickavelan, Faiza Zakaria, Julia Hanna, Muhammad Sanusi, Parjanya Bhatt, Rana Haddad, Fawaz Mohammed,
and et al. 2026. "Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence" Journal of Molecular Pathology 7, no. 3: 25.
https://doi.org/10.3390/jmp7030025
APA Style
Vempati, R., Toquica Gahona, C., Haddad, F., Manickavelan, H. V., Zakaria, F., Hanna, J., Sanusi, M., Bhatt, P., Haddad, R., Mohammed, F., Mylavarapu, M., Reddy, Y. M., & Nair, R.
(2026). Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence. Journal of Molecular Pathology, 7(3), 25.
https://doi.org/10.3390/jmp7030025
